Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Small Cell Lung Carcinoma 1Lung Neoplasms 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 71Paclitaxel 49Radiotherapy 44Pemetrexed 42Cisplatin 41Bevacizumab 39Gemcitabine 27Docetaxel 27Erlotinib Hydrochloride 23Gefitinib 18pembrolizumab 14Taxes 13Vinorelbine 10Cetuximab 10Radiation 8Nivolumab 8Magnetic Resonance Spectroscopy 8capmatinib 7Radiosurgery 7Platinum 7Etoposide 7Surgical Procedures, Operative 6Radiotherapy, Conformal 6Mastectomy, Segmental 6ceritinib 5aflutinib 5Specimen Handling 5Neoadjuvant Therapy 5Cyclophosphamide 5Biopsy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × Capsules × Thoracic × Clear all
NCT04105270 2025-09-11

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
82 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡